Trial Innovation Beyond the COVID-19 Pandemic
A look into the future based off what we've learned about trials during the pandemic.
As of Sept. 1, 2020, ClinicalTrials.gov lists 284 clinical trials as suspended. Not all of those trials are suspended for COVID-19, some are holdovers on financial issues, R&D problems, etc. And while upwards of 1,200 trials were suspended at the peak,
Solutions to enhance patient participation
According to press releases and reports of the time, solutions to ensure that participants could continue to stay in clinical trials safely were on the rise. In
During the pandemic, service providers offering safe patient access and decentralized model enablement, found increased interest in their business. Darcy Forman, vice president of clinical operations for Science 37, a provider of virtual clinical trials, commented at the time, “We have been unbelievably busy with this pandemic as sponsors are wanting to transition to a virtual model. It’s really accelerating, and they are finally pushing through their hesitancy.”
In
That sense of urgency and can-do attitude is what our event will highlight. We are currently recruiting speakers to share their experiences in the following topic areas: the patient participation piece; the New Clinical Trial and how sites and sponsors transitioned to address the barriers of COVID; and Ensuring Data Quality and eSource Implementation—again another “old is new again” strategy to gain forward momentum in the clinical trial discourse. We look forward to sharing your ideas during this forum.
Lisa Henderson is Editor-in-Chief of Applied Clinical Trials. She can be reached at
Articles in this issue
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Operational Strategies That Strengthened the NIMBLE Trial Design
September 16th 2025
- NIMBLE Trial Reveals New Insights on Complement Inhibition in gMG
September 15th 2025
- What Resilient Trial Design Means for Clinical Teams
September 2nd 2025
- Reimagining Clinical Trials for Remote Populations
August 29th 2025